Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E2022 Tape Formulation Study in Japanese Healthy Elderly Males
NCT02225288Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Sep 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of E2022 in Alzheimer's disease (AD) (4 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Number and frequency of adverse events. Started Sep 2014; status: completed.
02
Drugs
E2022
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02225288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02225288.